Novartis sets sights on Philly amid a sweeping CAR-T collaboration


Novartis ($NVS) has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers on a promising new approach to treating cancer. The company's new building is an 88,000-square-foot office space in King of Prussia, according to the Philadelphia Business Journal, whose sources say Novartis is moving in with aims of acquiring a local outfit. Meanwhile, in nearby University City, Novartis is working with Penn on therapies that re-engineer a patient's T cells to create cancer treatments called CAR-Ts, and the drugmaker has earmarked $20 million to help construct a 30,000-square-foot research center on campus. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.